Doximity Inc (DOCS)
29.86
+0.26
(+0.88%)
USD |
NYSE |
Jun 14, 16:00
29.29
-0.57
(-1.91%)
After-Hours: 20:00
Doximity Research and Development Expense (Quarterly): 20.15M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 20.15M |
| December 31, 2023 | 19.95M |
| September 30, 2023 | 19.96M |
| June 30, 2023 | 21.93M |
| March 31, 2023 | 21.54M |
| December 31, 2022 | 20.52M |
| September 30, 2022 | 19.10M |
| June 30, 2022 | 19.02M |
| Date | Value |
|---|---|
| March 31, 2022 | 17.42M |
| December 31, 2021 | 16.22M |
| September 30, 2021 | 15.46M |
| June 30, 2021 | 13.24M |
| March 31, 2021 | 12.56M |
| December 31, 2020 | 11.41M |
| September 30, 2020 | 9.866M |
| June 30, 2020 | 10.04M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
9.866M
Minimum
Sep 2020
21.93M
Maximum
Jun 2023
16.77M
Average
18.22M
Median
Research and Development Expense (Quarterly) Benchmarks
| Sharecare Inc | 14.54M |
| Definitive Healthcare Corp | 10.13M |
| Spok Holdings Inc | 2.951M |
| Ontrak Inc | 1.078M |
| FOXO Technologies Inc | -0.024M |